AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellon, S.
Right arrow Articles by Gross, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellon, S.
Right arrow Articles by Gross, C. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1856-1864, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1856-1864.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Crystal Structures of Escherichia coli Topoisomerase IV ParE Subunit (24 and 43 Kilodaltons): a Single Residue Dictates Differences in Novobiocin Potency against Topoisomerase IV and DNA Gyrase

Steven Bellon,{dagger} Jonathan D. Parsons, Yunyi Wei,* Koto Hayakawa, Lora L. Swenson, Paul S. Charifson, Judith A. Lippke, Robert Aldape, and Christian H. Gross

Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139

Received 10 September 2003/ Returned for modification 30 November 2003/ Accepted 31 January 2004

Topoisomerase IV and DNA gyrase are related bacterial type II topoisomerases that utilize the free energy from ATP hydrolysis to catalyze topological changes in the bacterial genome. The essential function of DNA gyrase is the introduction of negative DNA supercoils into the genome, whereas the essential function of topoisomerase IV is to decatenate daughter chromosomes following replication. Here, we report the crystal structures of a 43-kDa N-terminal fragment of Escherichia coli topoisomerase IV ParE subunit complexed with adenylyl-imidodiphosphate at 2.0-Å resolution and a 24-kDa N-terminal fragment of the ParE subunit complexed with novobiocin at 2.1-Å resolution. The solved ParE structures are strikingly similar to the known gyrase B (GyrB) subunit structures. We also identified single-position equivalent amino acid residues in ParE (M74) and in GyrB (I78) that, when exchanged, increased the potency of novobiocin against topoisomerase IV by nearly 20-fold (to 12 nM). The corresponding exchange in gyrase (I78 M) yielded a 20-fold decrease in the potency of novobiocin (to 1.0 µM). These data offer an explanation for the observation that novobiocin is significantly less potent against topoisomerase IV than against DNA gyrase. Additionally, the enzyme kinetic parameters were affected. In gyrase, the ATP Km increased {approx}5-fold and the Vmax decreased {approx}30%. In contrast, the topoisomerase IV ATP Km decreased by a factor of 6, and the Vmax increased {approx}2-fold from the wild-type values. These data demonstrate that the ParE M74 and GyrB I78 side chains impart opposite effects on the enzyme's substrate affinity and catalytic efficiency.


* Corresponding author. Mailing address: Christian H. Gross, Vertex Pharmaceuticals, Inc., 130 Waverly St., Cambridge, MA 02139. Phone: (617) 444-6768. E-mail: Christian_Gross{at}vrtx.com. Address crystallographic inquiries to Yunyi Wei. Mailing address: Vertex Pharmaceuticals, Inc., 130 Waverly St., Cambridge, MA 02139. Phone: (617) 444-6717. E-mail: Yunyi_Wei{at}vrtx.com.

{dagger} Present address: Amgen Inc., One Kendall Square, Cambridge, MA 02139.


Antimicrobial Agents and Chemotherapy, May 2004, p. 1856-1864, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1856-1864.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.